Open AccessDecline in neutralising antibody responses, but sustained T‐cell immunity, in COVID‐19 patients at 7 months post‐infection
Author(s) -
Chen Jun,
Liu Xiaomin,
Zhang Xinyu,
Lin Yixiao,
Liu Danping,
Xun Jingna,
Wang Zhenyan,
Gu Ling,
Li Qian,
Yin Dan,
Yang Junyang,
Lu Hongzhou
Publication year - 2021
Publication title -
clinical and translational immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.321
H-Index - 34
ISSN - 2050-0068
DOI - 10.1002/cti2.1319
Subject(s) - antibody , immune system , immunology , cd8 , humoral immunity , immunity , medicine , t cell , covid-19 , coronavirus , biology , disease , virology , infectious disease (medical specialty)
Objectives This study aimed to explore the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)‐specific humoral responses and T‐cell responses in patients who have recovered from coronavirus disease 2019 (COVID‐19) to understand the natural protective immune responses and to facilitate the development of vaccines. Methods We conducted a combined assessment of the changes in neutralising antibody levels and SARS‐CoV‐2‐specific T‐cell responses over time in 27 patients up to 7 months after infection. Results The neutralising antibody remained detectable in 96.3% of the patients at their second visit at about 7 months post‐onset of symptoms. However, their humoral responses, including titres of the spike receptor‐binding domain IgG and neutralising antibody, decreased significantly compared with those at first clinic visit. By contrast, the proportions of spike‐specific CD4 + T cells, but not CD8 + T cells, in COVID‐19 patients after recovery were persistently higher than those in healthy controls. No significant change was observed in the proportion of spike‐specific CD4 + T cells in patients who had recovered from COVID‐19 within 7 months. Conclusion The SARS‐CoV‐2‐specific T‐cell immune responses persisted, while the neutralising antibodies decayed. Further studies are needed to extend the longevity of neutralising antibodies and to evaluate whether these T cells are sufficient to protect patients from reinfection.